Covidien Pharmaceuticals Outsourcing

Covidien Pharmaceuticals Outsourcing - Pharmaceutical Contract Manufacturer Focusing on Solid and Oral Liquid Dosage Forms

Mallinckrodt, a company with a long history and wide range of pharmaceutical manufacturing experience, and its former parent company Tyco Healthcare are now Covidien.

Covidien is a global healthcare products company that manufactures, distributes and services a diverse range of industry-leading product lines, including pharmaceutical products, medical devices/ supplies, diagnostic imaging agents, and other healthcare products and services. With 2007 revenue of nearly $10 billion, Covidien’s products and services are sold in more than 130 countries.

NUMBER OF EMPLOYEES

Worldwide 43,000, with over 3,000 in the Pharmaceutical Products segment

KEY PERSONNEL

  • Daniel F. Casey, General Manager - Covidien Pharmaceuticals Outsourcing
  • Dale Dyer, Marketing Manager- Covidien Pharmaceuticals Outsourcing

GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING

Covidien Pharmaceuticals Outsourcing is focused on providing the most responsive and flexible service in the industry. The goal is simply to be first in class. As part of Covidien, the contract manufacturing business is better positioned than ever to provide customers with effective strategies and superior service to meet production goals, timelines, and budgets. Covidien Pharmaceuticals Outsourcing is a leader in developing and manufacturing high-quality solid dose and oral liquid finished dosage products from API production through to commercial launch. Additionally, through a new industry alliance, the company is now able to offer services including formulation development and clinical trial services.

Covidien Pharmaceuticals Outsourcing is a leader in operational excellence programs such as lean manufacturing and Six Sigma, ensuring that products are manufactured efficiently to maintain cost. Moreover, its Hobart, N.Y., cGMP facility is DEA compliant for Schedule I through V products.

With strong financial resources for growth, unmatched technical expertise, and deep regulatory knowledge, Covidien Pharmaceuticals Outsourcing is a partner that can give your project the high level of attention and accountability it deserves.

MAJOR MARKETS

Covidien is a global company with products and services sold in more than 130 countries. Covidien Pharmaceuticals Outsourcing has experience working with a diverse clientele, ranging from leading global companies to virtual and emerging entities. The company has a demonstrated record with the FDA as well as with customers, many who have outsourced with the company for more than 20 years.

CONTRACT MANUFACTURING CAPABILITIES

Our expert professionals are able to take your project from API sourcing to commercial launch.

MAJOR CAPABILITIES INCLUDE:

  • Solid dose tablets: immediate release, extended release
  • Hard shell capsules: IR, ER, liquid, powder, beads, overencapsulation, tablet within a capsule
  • Oral non-sterile liquids

MAJOR PHARMACEUTICAL MANUFACTURING SERVICES INCLUDE:

  • Bulk API
  • Process development
  • Analytical method development and validation
  • Clinical trial materials manufacturing
  • Technical transfer, scale-up and validation
  • QA/QC and stability testing programs
  • Regulatory consultation/submission (IND, NDA, ANDA)
  • Commercial scale-up and validation
  • Commercial manufacturing (DEA Compliant)
  • Commercial packaging (bottles and unit dose blister with bar coding

Covidien Pharmaceuticals Outsourcing
172 Railroad Avenue
PO Box P
Hobart
NY 13788-0416
USA
Contact: Daniel Casey, General Manager
Contact: Dale Dyer, Marketing Manager
Tel: +1 606 538 2093
Fax: +1 607 538 2511
Email: lili.smith@tycohealthcare.com
URL: www.pharmaceuticals.mallinckrodt.com/outsourcing

Printable Version Print friendly version

Regional Offices Regional Offices


Send an Enquiry





Expand Image
The finished product manufacturing facility in Hobart, NY is FDA and DEA I-V compliant and is operated under cGMP conditions.
The finished product manufacturing facility in Hobart, NY is FDA and DEA I-V compliant and is operated under cGMP conditions.
Expand Image
Covidien has added over  350 ,000ft² of manufacturing and packaging suites to the Hobart, New York site.
Covidien has added over 350 ,000ft² of manufacturing and packaging suites to the Hobart, New York site.
Expand Image
Covidien has invested over $150 million in the Hobart facility since 1996, including oral non-sterile liquid production, high-speed encapsulation and tablet presses.
Covidien has invested over $150 million in the Hobart facility since 1996, including oral non-sterile liquid production, high-speed encapsulation and tablet presses.
Expand Image
New packaging capabilities include unit dose with bar coded blister packs.
New packaging capabilities include unit dose with bar coded blister packs.
Expand Image
Facilities undergo regular audits by both regulatory agencies and clients to ensure that quality standards are met and exceeded.
Facilities undergo regular audits by both regulatory agencies and clients to ensure that quality standards are met and exceeded.
client logon
Home
Industry Projects
Company A-Z
White Papers
Jobs & Careers
Press Releases
Advertise With Us
Events & Exhibitions
Newsletter
New On This Site
About Us
Atom FeedRSS Feed
What is RSS?